Europe In Vitro Diagnostics Market by Product & Service(Chemicals &Reagents, Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Others), Application (Infectio

Europe In Vitro Diagnostics Market by Product & Service(Chemicals &Reagents, Instruments, and Software & Services), Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Others), Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and End User (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care, and Others): Opportunity Analysis and Industry Forecast, 2020–2027

The Europe in vitro diagnostics market (IVD) was valued at $13,825 million in 2019, and is projected to reach $18,647 million at a CAGR of 4.8% from 2020 to 2027.

In vitro diagnostics (IVD) are defined as medical devices and reagents, which are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from human body to detect diseases, conditions, and infections. The tests can be performed in standalone laboratory, hospital-based laboratory, and point-of-care centers. Some significant technologies incorporated in in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation. Moreover, other techniques that are used to perform in vitro diagnosis involve clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and others. For instance, in clinical chemistry various tests are performed in laboratory such as liver panel test, lipid profile, thyroid function test, and others.

Furthermore, a thyroid function test is performed by collecting blood from a patient, which is then tested to check the level of thyroid stimulating hormone (TSH) in blood. Similarly, others such as polymerase chain reaction (PCR) are used to detect the presence of infectious diseases such as HIV and hepatitis. In addition, constant innovations related to IVD products, service designs, and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. For instance, some products that are used to perform various in vitro diagnostic tests using various technologies involve real time PCR detection systems, immunoassay systems, and others.

The major factor that contributes to the growth of the Europe in vitro diagnostic market include surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels the growth of the market. In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict the growth of the Europe in vitro diagnostics market. On the contrary, potential for outsourcing present lucrative opportunities for key players in the Europe in vitro diagnostics market during the forecast period.

The report segments the market into product & service, technique, application, end user, and region. On the basis of product & service, it is segmented into chemicals & reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.

On the basis of application, the market is segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Country wise, the market is analyzed across Germany, France, the UK, Italy, Spain, and rest of Europe.

The major players in the in vitro diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current Europe in vitro diagnostics market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Product & Service

Chemicals & Reagents
Instruments
Software and Services

By Technique

Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Fluorescence immunoassay (FIA)
Colorimetric Immunoassay (CI)
Rapid Tests
Enzyme-Linked ImmunoSpot (ELISPOT)
Radioimmunoassay (RIA)
Western Blot
Hematology
Molecular Diagnostics
Polymerize Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA diagnostics
Microarray
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Electrolyte Panel
Specialty Chemicals
Others

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others

By End User

Standalone Laboratories
Hospitals
Academic & Medical Schools
Point-of-Care
Others

By Country

Germany
France
UK
Italy
Spain
Rest of Europe
List of key players profiled in the report:
Abbott Laboratories
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories, Inc.
Danaher Corporation (Beckman Coulter, Inc.)
F. Hoffmann-La Roche AG
Siemens AG
QIAGEN N.V.
Sysmex Corporation
Thermo Fisher Scientific, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

DiaSorin
Johnson & Johnson


CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top winning strategies, 2019
3.4.Market Share Analysis, 2019
3.5.Porters five forces analysis
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Increase in incidences of chronic and infectious diseases
3.6.1.2.Technological advancements in IVD
3.6.1.3.Rise in adoption of in vitro diagnostic testing
3.6.1.4.Rise in geriatric population
3.6.1.5.Increase in popularity of personalized medicine approach
3.6.2.Restraint
3.6.2.1.Unclear reimbursement policies
3.6.2.2.Stringent regulatory policies
3.6.3.Opportunity
3.6.3.1.Potential opportunities for outsourcing
3.6.4.Impact Analysis
3.7.COVID-19 Impact Analysis
CHAPTER 4:IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
4.1.Overview
4.1.1.Market size and forecast
4.2.Chemicals & Reagents
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by country
4.2.3.Market share analysis, by country
4.3.Instruments
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by country
4.3.3.Market share analysis, by country
4.4.Software & Services
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by country
4.4.3.Market share analysis, by country
CHAPTER 5:IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
5.1.Overview
5.1.1.Market size and forecast
5.2.Immunodiagnostics
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by country
5.2.3.Market share analysis, by country
5.2.4.Market size and forecast, by type
5.2.4.1.Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1.1.Market size and forecast, by type
5.2.4.1.2.Chemiluminescence Immunoassay (CLIA)
5.2.4.1.2.1.Market size and forecast
5.2.4.1.3.Fluorescence immunoassay (FIA)
5.2.4.1.3.1.Market size and forecast
5.2.4.1.4.Colorimetric Immunoassay (CI)
5.2.4.1.4.1.Market size and forecast
5.2.4.2.Rapid Tests
5.2.4.2.1.Market size and forecast
5.2.4.3.Enzyme-linked immunospot (ELISPOT)
5.2.4.3.1.Market size and forecast
5.2.4.4.Radioimmunoassay (RIA)
5.2.4.4.1.Market size and forecast
5.2.4.5.Western blot
5.2.4.5.1.Market size and forecast
5.3.Hematology
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by country
5.3.3.Market share analysis, by country
5.4.Molecular diagnostics
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by country
5.4.3.Market share analysis, by country
5.4.4.Market size and forecast, by type
5.4.4.1.Polymerize chain reaction (PCR)
5.4.4.1.1.Market size and forecast
5.4.4.2.Isothermal Nucleic acid amplification technology (INAAT)
5.4.4.2.1.Market size and forecast
5.4.4.3.Hybridization
5.4.4.3.1.Market size and forecast
5.4.4.4.DNA diagnostics
5.4.4.4.1.Market size and forecast
5.4.4.5.Microarray
5.4.4.5.1.Market size and forecast
5.4.4.6.Others
5.4.4.6.1.Market size and forecast
5.5.Tissue diagnostics
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by country
5.5.3.Market share analysis, by country
5.6.Clinical chemistry
5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast, by country
5.6.3.Market share analysis, by country
5.6.4.Market size and forecast, by type
5.6.4.1.Basic metabolic panel
5.6.4.1.1.Market size and forecast
5.6.4.2.Liver panel
5.6.4.2.1.Market size and forecast
5.6.4.3.Renal profile
5.6.4.3.1.Market size and forecast
5.6.4.4.Lipid profile
5.6.4.4.1.Market size and forecast
5.6.4.5.Thyroid function panel
5.6.4.5.1.Market size and forecast
5.6.4.6.Electrolyte panel
5.6.4.6.1.Market size and forecast
5.6.4.7.Specialty chemicals
5.6.4.7.1.Market size and forecast
5.7.Others
5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast, by country
5.7.3.Market share analysis, by country
CHAPTER 6:IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Infectious Diseases
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.3.Market share analysis, by country
6.3.Cancer
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.3.Market share analysis, by country
6.4.Cardiac diseases
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.3.Market share analysis, by country
6.5.Immune system disorders
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.3.Market share analysis, by country
6.6.Nephrological diseases
6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by country
6.6.3.Market share analysis, by country
6.7.Gastrointestinal diseases
6.7.1.Key market trends, growth factors, and opportunities
6.7.2.Market size and forecast, by country
6.7.3.Market share analysis, by country
6.8.Others
6.8.1.Key market trends, growth factors, and opportunities
6.8.2.Market size and forecast, by country
6.8.3.Market share analysis, by country
CHAPTER 7:IN VITRO DIAGNOSTICS MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Standalone Laboratories
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market share analysis, by country
7.3.Hospitals
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market share analysis, by country
7.4.Academic and medical schools
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market share analysis, by country
7.5.Point-of-care testing
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market share analysis, by country
7.6.Others
7.6.1.Key market trends, growth factors, and opportunities
7.6.2.Market size and forecast, by country
7.6.3.Market share analysis, by country
CHAPTER 8:IN VITRO DIAGNOSTICS MARKET, BY COUNTRY
8.1.Overview
8.1.1.Key market trends, growth factors, and opportunities
8.1.2.Market size and forecast, by country
8.1.2.1.Germany
8.1.2.2.Market size and forecast
8.1.2.2.1.Germany in vitro diagnostics market, by product & service
8.1.2.2.2.Germany In vitro diagnostics market, by technique
8.1.2.2.3.Germany In vitro diagnostics market, by application
8.1.2.2.4.Germany In vitro diagnostics market, by end user
8.1.2.3.France
8.1.2.4.Market size and forecast
8.1.2.4.1.France In vitro diagnostics market, by product & service
8.1.2.4.2.France In vitro diagnostics market, by technique
8.1.2.4.3.France In vitro diagnostics market, by application
8.1.2.4.4.France In vitro diagnostics market, by end user
8.1.2.5.UK
8.1.2.6.Market size and forecast
8.1.2.6.1.UK In vitro diagnostics market, by product & service
8.1.2.6.2.UK In vitro diagnostics market, by technique
8.1.2.6.3.UK In vitro diagnostics market, by application
8.1.2.6.4.UK In vitro diagnostics market, by end user
8.1.2.7.Italy
8.1.2.8.Market size and forecast
8.1.2.8.1.Italy in vitro diagnostics market, by product & service
8.1.2.8.2.Italy In vitro diagnostics market, by technique
8.1.2.8.3.Italy In vitro diagnostics market, by application
8.1.2.8.4.Italy In vitro diagnostics market, by end user
8.1.2.9.Spain
8.1.2.10.Market size and forecast
8.1.2.10.1.Spain In vitro diagnostics market, by product & service
8.1.2.10.2.Spain In vitro diagnostics market, by technique
8.1.2.10.3.Spain In vitro diagnostics market, by application
8.1.2.10.4.Spain In vitro diagnostics market, by end user
8.1.2.11.Rest of Europe
8.1.2.12.Market size and forecast
8.1.2.12.1.Rest of Europe In vitro diagnostics market, by product & service
8.1.2.12.2.Rest of Europe In vitro diagnostics market, by technique
8.1.2.12.3.Rest of Europe In vitro diagnostics market, by application
8.1.2.12.4.Rest of Europe In vitro diagnostics market, by end user
CHAPTER 9:COMPANY PROFILES
9.1.ABBOTT LABORATORIES
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product and service portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.BECTON, DICKINSON AND COMPANY
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product and service portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.BIOMÉRIEUX SA
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product and service portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments
9.4.BIO-RAD LABORATORIES, INC.
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product and service portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments
9.5.DANAHER CORPORATION (BECKMAN COULTER, INC.)
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product and service portfolio
9.5.5.Business performance
9.5.6.Key strategic moves and developments
9.6.F. HOFFMANN-LA ROCHE AG.
9.6.1.Company snapshot
9.6.2.Operating business segments
9.6.3.Product and service portfolio
9.6.4.Business performance
9.6.5.Key strategic moves and developments
9.7.QIAGEN N.V.
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product and service portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments
9.8.SIEMENS AG (SIEMENS HEALTHINEERS)
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.8.6.Key strategic moves and developments
9.9.SYSMEX CORPORATION
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product and service portfolio
9.9.5.Business performance
9.10.THERMO FISHER SCIENTIFIC, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product and service portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.ESTIMATED GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2018
TABLE 02.TYPES OF IN VITRO DIAGNOSTIC PRODUCTS AVAILABLE FOR COVID-19 DIAGNOSIS
TABLE 03.IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027 ($MILLION)
TABLE 04.IN VITRO DIAGNOSTICS MARKET FOR CHEMICAL & REAGENTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 05.IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 06.IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019–2027 ($MILLION)
TABLE 07.IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 ($MILLION)
TABLE 08.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 09.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2019–2027 ($MILLION)
TABLE 10.IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY TYPE, 2019–2027 ($MILLION)
TABLE 11.IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 12.IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 13.MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 14.IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 16.CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 17.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 18.IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 19.IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 20.IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,2019–2027 ($MILLION)
TABLE 21.IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 22.IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY,2019–2027 ($MILLION)
TABLE 23.IN VITRO DIAGNOSTICS MARKET FOR NEPROLOGICAL DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 24.IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 25.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY,2019–2027 ($MILLION)
TABLE 26.IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 27.IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 29.IN VITRO DIAGNOSTICS MARKET FOR ACADEMICS & MEDICAL SCHOOLS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 31.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 32.EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 33.GERMANY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 34.GERMANY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 35.GERMANY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 36.GERMANY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 37.FRANCE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 38.FRANCE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 39.FRANCE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 40.FRANCE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 41.UK IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 42.UK IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 43.UK IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 44.UK IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 45.ITALY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 46.ITALY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 47.ITALY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 48.ITALY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 49.SPAIN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 50.SPAIN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 51.SPAIN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 52.SPAIN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 53.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 54.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 55.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 56.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 57.ABBOTT: COMPANY SNAPSHOT
TABLE 58.ABBOTT: OPERATING SEGMENTS
TABLE 59.ABBOTT: PRODUCT AND SERVICE PORTFOLIO
TABLE 60.BD : COMPANY SNAPSHOT
TABLE 61.BD : OPERATING SEGMENTS
TABLE 62.BD: PRODUCT AND SERVICE PORTFOLIO
TABLE 63.BIOMÉRIEUX: COMPANY SNAPSHOT
TABLE 64.BIOMÉRIEUX: OPERATING SEGMENTS
TABLE 65.BIOMÉRIEUX: PRODUCT AND SERVICE PORTFOLIO
TABLE 66.BIO-RAD: COMPANY SNAPSHOT
TABLE 67.BIO-RAD: OPERATING SEGMENTS
TABLE 68.BIO-RAD: PRODUCT AND SERVICE PORTFOLIO
TABLE 69.DANAHER: COMPANY SNAPSHOT
TABLE 70.DANAHER: OPERATING SEGMENTS
TABLE 71.DANAHER: PRODUCT AND SERVICE PORTFOLIO
TABLE 72.ROCHE: COMPANY SNAPSHOT
TABLE 73.ROCHE: OPERATING SEGMENTS
TABLE 74.ROCHE: PRODUCT AND SERVICE PORTFOLIO
TABLE 75.QIAGEN: COMPANY SNAPSHOT
TABLE 76.QIAGEN: OPERATING SEGMENTS
TABLE 77.QIAGEN: PRODUCT AND SERVICE PORTFOLIO
TABLE 78.SIEMENS: COMPANY SNAPSHOT
TABLE 79.SIEMENS: OPERATING SEGMENTS
TABLE 80.SIEMENS: PRODUCT PORTFOLIO
TABLE 81.SYSMEX: COMPANY SNAPSHOT
TABLE 82.SYSMEX: OPERATING SEGMENTS
TABLE 83.SYSMEX: PRODUCT AND SERVICE PORTFOLIO
TABLE 84.THERMO FISHER: COMPANY SNAPSHOT
TABLE 85.THERMO FISHER: OPERATING SEGMENTS
TABLE 86.THERMO FISHER SCIENTIFIC: PRODUCT AND SERVICE PORTFOLIO
LIST OF FIGURES
FIGURE 01.IN-VITRO DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02.TECHNIQUE MARKET SUB-SEGMENTATION
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.TOP WINNING STRATEGIES, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 07.MARKET SHARE ANALYSIS, 2019
FIGURE 08.BARGANING POWER OF BUYERS
FIGURE 09.BARGANING POWER OF SUPPLIERS
FIGURE 10.THREAT OF SUBSTITUTIONS
FIGURE 11.THREAT OF NEW ENTRANTS
FIGURE 12.MODERATE COMPETITIVE RIVALRY
FIGURE 13.IMPACT ANALYSIS, IN-VITRO DIAGNOSTICS MARKET
FIGURE 14.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CHEMICALS & REAGENTS, BY COUNTRY, 2019 & 2027
FIGURE 15.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019 & 2027
FIGURE 16.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2019 & 2027
FIGURE 17.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019 & 2027
FIGURE 18.IMMUNODIAGNOSTICS MARKET FOR ENZYME LINKED IMMUNOSORBENT ASSAY, 2019–2027 ($MILLION)
FIGURE 19.IMMUNODIAGNOSTICS MARKET FOR RAPID TESTS, 2019–2027 ($MILLION)
FIGURE 20.IMMUNODIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT (ELISPOT), 2019–2027 ($MILLION)
FIGURE 21.IMMUNODIAGNOSTICS MARKET FOR RADIOIMMUNOASSAY (RIA), 2019–2027 ($MILLION)
FIGURE 22.IMMUNODIAGNOSTICS MARKET FOR WESTERN BLOT, 2019–2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019 & 2027
FIGURE 24.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019 & 2027
FIGURE 25.MOLECULAR DIAGNOSTICS MARKET FOR POLYMERIZE CHAIN REACTION (PCR), 2019–2027 ($MILLION)
FIGURE 26.MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), 2019–2027 ($MILLION)
FIGURE 27.MOLECULAR DIAGNOSTICS MARKET FOR HYBRIDIZATION, 2019–2027 ($MILLION)
FIGURE 28.MOLECULAR DIAGNOSTICS MARKET FOR DNA DIAGNOSTICS, 2019–2027 ($MILLION)
FIGURE 29.MOLECULAR DIAGNOSTICS MARKET FOR MICROARRAY, 2019–2027 ($MILLION)
FIGURE 30.MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, 2019–2027 ($MILLION)
FIGURE 31.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019 & 2027
FIGURE 32.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019 & 2027
FIGURE 33.CLINICAL CHEMISTRY MARKET FOR BASIC METABOLIC PANEL, 2019–2027 ($MILLION)
FIGURE 34.CLINICAL CHEMISTRY MARKET FOR LIVER PANEL, 2019–2027 ($MILLION)
FIGURE 35.CLINICAL CHEMISTRY MARKET FOR RENAL PROFILE, 2019–2027 ($MILLION)
FIGURE 36.CLINICAL CHEMISTRY MARKET FOR LIPID PROFILE, 2019–2027 ($MILLION)
FIGURE 37.CLINICAL CHEMISTRY MARKET FOR THYROID FUNCTION PANEL, 2019–2027 ($MILLION)
FIGURE 38.CLINICAL CHEMISTRY MARKET FOR ELECTROLYTE PANEL, 2019–2027 ($MILLION)
FIGURE 39.CLINICAL CHEMISTRY MARKET FOR SPECIALTY CHEMICALS, 2019–2027 ($MILLION)
FIGURE 40.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027
FIGURE 41.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 42.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2019 & 2027
FIGURE 43.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 44.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY, 2019 & 2027
FIGURE 45.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 46.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 47.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 48.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019 & 2027
FIGURE 49.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027
FIGURE 50.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR ACADEMICS & MEDICAL SCHOOLS, BY COUNTRY, 2019 & 2027
FIGURE 51.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027
FIGURE 52.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027
FIGURE 53.GERMANY IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 54.FRANCE IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 55.UK. IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 56.ITALY IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 57.SPAIN IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 58.REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 59.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 60.ABBOTT: NET SALES SHARE, BY OPERATING SEGMENT, 2019 (%)
FIGURE 61.ABBOTT: NET SALES SHARE, BY REGION, 2019 (%)
FIGURE 62.BD: REVENUE, 2017–2019 ($MILLION)
FIGURE 63.BD: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 64.BD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 65.BIOMÉRIEUX: NET SALES, 2016–2018 ($MILLION)
FIGURE 66.BIOMÉRIEUX: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 67.BIOMÉRIEUX: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 68.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 69.BIO-RAD: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 70.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 71.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 72.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 73.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 74.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 75.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 76.QIAGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 77.QIAGEN: REVENUE SHARE, BY PRODUCT AND SERVICE, 2019 (%)
FIGURE 78.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 79.NET SALES, 2017–2019 ($MILLION)
FIGURE 80.SIEMENS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 81.SIEMENS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 82.SYSMEX: REVENUE, 2017–2019 ($MILLION)
FIGURE 83.SYSMEX: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 84.SYSMEX: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 85.THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 86.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 87.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2018 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook